New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
09:17 EDTMDCOThe Medicines Co. says sees Q1 net revenue $145M-$155M, consensus $157.55M
Says sees GAAP EPS loss (33c)-(24c) for Q1, may not compare to consensus of 27c. Says Q1 will be "burdened" by a number of one-time business circumstances. Sees FY13 worldwide net revenue growth 20%-22%, consensus $655.13M. Comments made on the Q4 earnings conference call.
News For MDCO From The Last 14 Days
Check below for free stories on MDCO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 7, 2014
17:56 EDTMDCOThe Medicines Co. could have 25% upside, Barron's says
FDA approval of The Medicines Co. skin infection drug Orbactiv should give shares a boost and although the stock is not cheap, it is cheap enough to buy, Barron's argues in its Barron's Take column. The company's pipeline should bolster its earnings, the paper adds. Reference Link
08:12 EDTMDCOThe Medicines Co. to host conference call
Subscribe for More Information
05:11 EDTMDCOThe Medicines Co. Orbactiv approved by FDA
The Medicines Company announced that the FDA has approved Orbactiv for injection for the treatment of adults with acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus aureus. Orbactiv is the first and only antibiotic approved by FDA to treat ABSSSIs with a single, once-only administration. Once fully infused over three hours, the Orbactiv treatment regimen is complete for patients with skin infections caused by susceptible Gram-positive pathogens.
August 6, 2014
18:17 EDTMDCOFDA approves Orbactiv to treat skin infections
Subscribe for More Information
06:26 EDTMDCOFDA PDUFA Date for The Medicines Company Oritavancin is August 6, 2014

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use